Boehringer Ingelheim Kg

Boehringer Ingelheim Pharma Kg

Dr. Karl Thomae Gmbh

Boehringer Ingelheim Gmbh

Karl Thomae Gmbh

C. H. Boehringer Sohn

Neurosearch A/s

Joachim Mierau

Gunter Schingnitz

Rudolf Bauer

Herbert Merz

Claus S Schneider

Matthias Grauert

Rudolf Hurnaus

Walter Kobinger

Erich Lehr

Ludwig Pichler

Wolfram Gaida

Thomas Weiser

Adrian Carter

Helmut Ensinger

Rainer Sobotta

Dieter Hinzen

Gerhart Griss, Deceased

Matthias Hoffmann

Adolf Langbein

Gerald Pohl

Stefan Matthias Blech

Ulrike Kuefner-Muehl

Werner Kummer

Franz J Kuhn

Manfred Reiffen

Wolfgang Grell

Michael Entzeroth

Robert Sauter

Hans Michael Jennewein

Rudolf Hammer

Thomas Friedl

Christopher John Montague Meade

Ulrike Kufner-Muhl

Enzio Muller

Andreas Raschig

Franco Borsini

Ursula Gath

Jörgen Scheel-Krüger

Jürgen Reess

Imidazotriazolopyrimidines with adenosine-antagonistic activity

Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and their use as pharmaceutical compositions

The invention relates to the use of pramipexol as a pharmaceutical composition having an antidepressant activity.

Use of 2-amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole as a pharmaceutical composition having an antidepressant activity

Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity

Xanthine derivatives of formula ##STR1## wherein R.sub.1 is hydrogen, alkyl or alkynyl, R.sub.2 is different and is alkyl, alkynyl, phenyl-alkylene, phenyl alkenylene, cycloalkyl, inter alia, R.sub.3 is cycloalkyl, phenyl, norbornane, inter alia and R.sub.4 is hydrogen, methyl, benzyl, inter alia.

Asymmetrically substituted xanthines

The invention relates to novel 2,5-diaminotetralines of the formula: ##STR1## wherein R1, R2, R3 and R4 are defined herein, processes for preparing them and their use in pharmaceutical compositions. The novel 2,5-diaminotetralines are useful in treating diseases caused by disorders of the dopaminergic systems.

Method of treating disorders of the dopaminergic systems using

The present invention relates to new 4,5,7,8-tetrahydro-6H-thiazolo[5,4-d]azepines of general formula II ##STR1## wherein the substituents are defined herein below, which compounds have valuable pharmacological properties, namely selective effects on the dopaminergic system which are achieved by stimulating (predominantly D2) dopamine receptors.

4,5,7,8-tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and

Novel compounds having the general formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein. These compounds are useful in the treatment of schizophrenia.

Use of 2,7-diamino-1,2,3,4-tetrahydronaphthalenes as medicaments, new

3-Bromo-2,6-dimethoxybenzamides useful as neuroleptic agents are described.

Certain 3-bromo-2,6-dimethoxybenzamides and pharmaceutical use thereof

Tetrahydrobenzothiazole derivatives of the formula ##STR1## wherein n is 1, 2 or 3 and R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are defined substituents, said derivatives (I) being suitable as active compounds for treating parkinsonism or Parkinson's Disease.

Tetrahydrobenzothiazoles, and the preparation and use thereof

This invention relates to new tetrahydrobenzthiazoles of general formula ##STR1## wherein R.sub.1 represents a hydrogen atom, an alkyl group, an alkenyl or alkynyl group, an alkanoyl group, a phenyl alkyl or phenyl alkanoyl group, while the above mentioned phenyl nucleic may each be substituted by 1 or 2 halogen atoms, R.sub.2 represents a hydrogen atom or an alkyl group, R.sub.3 represents a hydrogen atom, an alkyl group a cycloalkyl group, an alkenyl or alkynyl group, an alkanoyl group, a phenyl alkyl or phenyl alkanoyl group, while the phenyl nucleus may be substituted by fluorine, chlorine or bromine atoms, R.sub.4 represents a hydrogen atom, an alkyl group, an alkyl or alkenyl group, or R.sub.3 and R.sub.4 together with the nitrogen atom between them represent a pyrrolidino, piperidino, hexamethyleneimino or morpholino group, the enantiomers and the acid addition salts thereof. The compounds of general formula I above in which one of the groups R.sub.1 or R.sub.3 or both groups R.sub.1 and R.sub.3 represent an acyl group are valuable intermediate products for preparing the other compounds of general formula I which have valuable pharmacological properties. The new compounds may be prepared using methods known per se.

Tetrahydro-benzthiazoles, the preparation thereof and their use as

This invention relates to new tetrahydrobenzthiazoles of general formula ##STR1## wherein R.sub.1 represents a hydrogen atom, an alkyl group, an alkenyl or alkynyl group, an alkanoyl group, a phenyl alkyl or phenyl alkanoyl group, while the above mentioned phenyl nuclei may each be substituted by 1 or 2 halogen atoms.

This invention relates to new tetrahydrobenzthiazoles of general formula ##STR1## wherein R.sub.1 represents a hydrogen atom, an alkyl group, an alkenyl or alkynylk group, an alkanoyl group, a phenyl alkyl or phenyl alkanoyl group, while the above mentioned phenyl nuclei may each be substituted by 1 or 2 halogen atoms,

Compounds of the formula ##STR1## wherein Ar is ##STR2## R.sub.1 is hydrogen, fluorine, bromine, methyl or methoxy; X is .dbd.CO, .dbd.CH--CN, .dbd.CH--OH, --O--, --S--, --NH--, ##STR3## and R is hydrogen, 4-fluoro, 4-chloro, 4-trifluoromethyl, 3-trifluoromethyl, 3-trifluoromethyl-4-chloro, 4-methyl or 4-methoxy; and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as their salts are useful as neuroleptics.

8-Arylalkyl-3-phenyl-3-nortropanols and salts thereof

Growing community of inventors

Mainz, Germany

Joachim Mierau